Activation of peroxisome proliferator-activated receptor gamma is crucial for antitumoral effects of 6-iodolactone

Mario Nava-Villalba1, Rosa E. Nuñez-Anita2, Alexander Bontempo1 and Carmen Aceves1*

Abstract

Background: Molecular iodine (I2) exhibits antiproliferative and apoptotic effects on in vivo and in vitro cancer models. These effects are thought to be mediated by an iodinated arachidonic acid derivative, 6-iodolactone (6IL), and one of the proposed mechanisms is that 6IL activates Peroxisome Proliferator-Activated Receptors type gamma (PPARG). These receptors have been implicated in the inhibition of carcinogenic processes, in addition to their classical role in maintaining lipid and glucose homeostasis. The aim of this study was to determine whether PPARG participates in the 6IL antiproliferative and apoptotic effects on the mammary cancer cell line MCF-7.

Methods: The 6IL/PPARG complex was inhibited by the PPARG antagonist GW9662, in both an endogenous and overexpressed (adenoviral vector infection) context, and stable PPARG-knockdown MCF-7 cells (RNA interference, confirmed with hydrolysis probes and Western blot), were used to corroborate the PPARG participation. 6IL effects on proliferation (measured by Trypan Blue exclusion) and apoptosis (phosphatidylserine identification by flow cytometry) were evaluated in conditions of chemical inhibition (GW9662) and silencing (RNA interference). A wound-healing assay was conducted on wild-type and stable PPARG-knockdown MCF-7 cells to evaluate the antimigrational effect of 6IL. Caspase-8 activity was evaluated to determine if the extrinsic pathway is involved in the effects of 6IL and I2 treatment.

Results: Antiproliferative and pro-apoptotic 6IL effects require the activation of PPARG. In addition, wound-healing assays show that 6IL is able to inhibit MCF-7 cell migration and that PPARG plays a role in this phenomenon. Finally, the data exclude the participation of the extrinsic apoptotic pathway in 6IL- and I2-induced apoptosis.

Conclusions: These results support the previously proposed mechanism, in which the I2 effects are mediated by 6IL, and they provide further support for the use of I2 as coadjuvant in breast cancer treatment.

Keywords: Iodine, Iodocompounds, PPARG, Arachidonic acid, Mammary cancer, MCF-7, Iodolactone

Background

6-Iodo-5-hydroxy-8,11,14-eicosatrienoic acid, δ-lactone (6-iodolactone or 6IL) is an iodinated arachidonic acid (AA) derivative and has been proposed to mediate the antitumoral effects of iodine [1–3]. Molecular iodine (I2), but not iodide (I−), exerts antineoplastic actions on diverse tissues (mammary, prostate and thyroid glands, and on melanoma, pancreas carcinoma and neuroblastoma cell lines), and various studies suggest that these effects can involve direct or indirect mechanisms [4–8]. In the direct effect, the oxidant/antioxidant property of I2 can disrupt the mitochondrial membrane potential and trigger mitochondrion-mediated apoptosis [6, 9]; on the other hand, the indirect path involves the generation of iodolipid intermediates, and there is evidence that 6IL could be one such intermediate. The presence of 6IL has been reported in normal and tumoral mammary gland from rats with continuous I2 supplements in their diet [2]. 6IL has also been observed in an in vitro model, in which an iodinated lipid co-migrating with the 6IL standard was detected in 125I2-treated MCF-7 cells [5].
At the molecular level, both I2 as 6IL generate antitumor effects through similar pathways. Both trigger a p53/p21-mediated cell growth arrest, and both induce Bax-caspases and AIF/PARP-1 apoptosis [1, 9]. In MCF-7 cells, 6IL supplement is accompanied by a significant stimulation of peroxisome proliferator-activated receptor type gamma (PPARG) and inhibition of PPAR alpha (PPARA) expression [10]. Moreover, using electrophoretic mobility shift assays (EMSAs), these authors demonstrated that 6IL is a PPAR ligand and can activate the PPAR response element (PPRE) (as shown by reporter gene transactivation assays). PPARs are involved in lipid metabolism, energy homeostasis and differentiation, and they have also been associated with positive or negative effects on carcinogenesis of various neoplasias [11–13]. While PPARA has been linked to carcinogenesis promotion [14, 15], PPARG or NR1C3 [16, 17] is proposed to be an antineoplastic agent, since it inhibits proliferation, induces apoptosis and promotes differentiation [18–22]. These opposing effects of PPARA and PPARG have been documented in normal and tumoral breast tissue and mammary cell lines [23, 24]. With respect to differentiation, 6IL induces cytoplasmic accumulation of lipid droplets, in a way comparable to that of the synthetic PPARG agonist rosiglitazone [10]. Thus, while previous work has shown a close relationship between PPARG and 6IL, here we use chemical and molecular approaches to demonstrate that the 6IL/PPARG complex is an intermediary in the antiproliferative and apoptotic effects of molecular iodine.

Results
GW9662 cancels the apoptotic and antiproliferative effects of 6IL
To demonstrate that PPARG activation plays a key role in the 6IL effects, we inhibited PPARG/6IL complex formation by blocking the PPARG ligand-binding domain with its highly specific antagonist GW9662. To determine the appropriate concentration of GW9662, i.e., a concentration that inhibited PPARG/6IL complex formation without causing the antiproliferative effects previously reported [25], we performed a dose–response curve (0.2 to 10 μM) for GW9662 in MCF-7 cells (Fig. 1a), and selected 0.5 μM

![Antiproliferative and apoptotic effect of 6IL is blocked by GW9662 (GW).](image-url)

*a MCF-7 cells were treated with increasing GW9662 concentrations to determine the optimal concentration that did not inhibit proliferation; 0.5 μM was selected for use in subsequent experiments. *b Proliferation in the presence of 10 μM 6IL and after GW pretreatment was analyzed by the Trypan Blue exclusion assay. *

c Apoptosis was analyzed by flow cytometry (c, d). Results are expressed as percent change with respect to the control. Data are expressed as mean ± SD (n = 4 independent assays), and the asterisk indicates a significant difference with respect to the control (P < 0.05)
for further experiments. Figure 1b shows that the 6IL supplement exerted a significant antiproliferative effect, which was prevented when the cells were pre-incubated (2 h) with GW9662. The 6IL treatment induced a significant, nearly two-fold increase in the apoptotic population compared to the control level (Fig. 1c-d), and this effect was blocked when the cells were pretreated with GW9662.

**Overexpression of PPARG enhances the antiproliferative and apoptotic effects of 6IL**

Figure 2a and b show the infection efficiency of MCF-7 with the GFP- and PPARG-adenoviral vectors, as measured by GFP intensity and mRNA amplification, respectively. Figure 2c shows the proliferation rate with ascending MOI (details in methods section), and a MOI...
of 50 was chosen for further experiments. Functional PPARG overexpression was confirmed by fatty acid synthase (FASN) expression, a PPARG-regulated gene (Fig. 2d). Figure 2e shows that the antiproliferative effect of the 6IL supplement was significantly intensified in the AdPPARG-infected group compared to the uninfected group, and that preincubation with GW9662 only partially prevented this pronounced effect. In contrast, the overexpression of PPARG increased the sensitivity of these cells to the apoptotic effect of 6IL, and this effect was strongly inhibited by GW9662 (Fig. 2f).

The silencing of PPARG expression blocks the antiproliferative and apoptotic effects of 6IL
To confirm the stable transfection of RNAi against PPARG mRNA in selected cells, GFP expression (from the GFP gene co-inserted with the RNAi into the HuSH™ plasmid) was assessed (Fig. 3a). PPARG silencing was confirmed by qPCR with specific Hydrolysis Probes (Fig. 3b and Table 1) and Western blot (Fig. 3c). Wild type (WT), Scramble-PPARG (Scramble) and RNAi-PPARG (RNAi) MCF-7 cells were treated with 10 μM 6IL over a 96-h period, and their proliferation rates were evaluated. Figure 3d shows that WT and Scramble-
PPARG MCF-7 cells had the same proliferation rates, whereas RNAi-PPARG MCF-7 cells exhibited significantly faster proliferation. The 6IL supplement inhibited proliferation of WT and Scramble-PPARG MCF-7 cells, whereas it had no effect on the PPARG-knockdown group (RNAi-PPARG). Figure 3e summarizes the apoptotic effect of 6IL in these groups, showing significant apoptosis on WT and Scramble-PPARG cells and no effect on RNAi-PPARG MCF-7 cells.

6IL inhibits MCF-7 cell migration, but this effect is blocked by silencing PPARG
Groups were treated for 24 h with 10 μM 6IL or vehicle, and the migration rate was evaluated by a wound-healing assay (Fig. 4a). WT and Scramble-PPARG MCF-7 cells treated with 6IL showed significant inhibition of migration, around 60%; however, 6IL did not change the migration rate of RNAi-PPARG MCF-7 cells (Fig. 4b).

### Table 1 Real-time PCR primer sequences

| Gene     | Sequence (5′–3′) | Annealing temp (°C) | ID               |
|----------|------------------|---------------------|------------------|
| FASN     | Sense            | GGAATGGGAAGACACCCTATGGA | 62               | GenBank NM_004104.4 |
|          | Antisense        | AGAGAGAGACTGATCTGCAGTGGC |               |                      |
| PPARG    | Sense            | TTCCTCGCTTACAGCAGGACCC | 62               | GenBank L40904.2    |
|          | Antisense        | GCATTATGAAGACATCCCGAAC |               |                      |
| ACTB     | Sense            | CCCATCATGAGCTTGGACGTGTC | 62               | GenBank NM_001101.3 |
|          | Antisense        | ACAGAGAATCGCTGCAAGG |               |                      |
| PPARG Hydrolysis Probe | Sense | GATGTCTCTGTGAGGACATGGTT | 60               | RTPrimerDB ID: 5471 |
|          | Antisense        | GGATTCAGCCTGCTGATATCTCAT |               |                      |
|          | Probe            | CCAACAGCCTCTCTTCTGGCTTG |               |                      |
| ACTB Hydrolysis Probe | Sense | TCCTTCTGGGCTCAGGAG | 60               | RTPrimerDB ID: 2418 |
|          | Antisense        | AGGAGAGCAGGATCTGATCTCTT |                |                      |
|          | Probe            | CCGCTGGGATTCACGAAACTCTTC |               |                      |

**Fig. 4** 6IL inhibits MCF-7 migration and this effect is partially reverted by PPARG knockdown. Wild type, Scramble- and RNAi-PPARG transfected MCF-7 cells were treated with 10 μM 6IL for 24 h, and the number of cells that had migrated into the scratch during this time was determined (10x objective, scale bar 200 μm, average scratch width 377 μm). **a** Representative microphotographs of wound-healing assays. **b** Migrating cells (total number). Data are expressed as mean ± SD (n = 3 independent assays), two-way ANOVA and Tukey’s multiple comparison tests were performed; different letters indicate significant differences between groups (P < 0.05).
The 6IL induction of apoptosis is not activated by the extrinsic pathway

To evaluate the participation of the extrinsic pathway in the 6IL or I₂ effects on apoptosis, caspase-8 activity was evaluated. Neither 10 μM 6IL nor 200 μM I₂ treatments produced any change in caspase-8 activity (Fig. 5).

Discussion

A significant body of data from in vivo experiments [4, 26–29], clinical trials [30–33], and epidemiological reviews [34–36] support the notion that molecular iodine has a protective effect against the progression of neoplastic diseases and inflammatory/proliferative pathologies. An important fact to consider is that these beneficial effects occur only at relatively high iodine concentrations (milligrams/day) and only in those tissues that are able to capture iodine. In the case of mammary and prostate glands, both normal and tumoral cells internalize I₂ by a sodium/iodine symporter (NIS)-independent mechanism [1, 4, 5, 8, 37] that seems to involve a facilitated diffusion process (saturable and dependent on protein synthesis) [5]. It has not yet been determined how I₂ reacts with cell components, but I₂ is known to bind covalently to proteins and lipids [5]. The iodination of fatty acids generates several derivatives, but those from arachidonic acid (AA), like 6IL, are especially relevant since endogenous 6IL has been detected [38, 39], and it generates a range of biological effects [3].

![Caspase-8 activity](image)

**Fig. 5** Extrinsic apoptotic pathway is not involved in the induction of apoptosis by 6IL or I₂. MCF-7 cells were treated with 10 μM 6IL or 100 μM I₂ for 48 h. Caspase-8 activity was analyzed by a colorimetric assay and normalized for the amount of protein. The results are reported as percent change with respect to the control. Data are expressed as mean ± SD (n = 3 independent assays). There were no significant differences between groups.

The proposal that PPARG plays a role in the antitumor effects exhibited by I₂ after its conversion to 6IL is supported by the following evidence: 1) 6IL can be identified in both in vitro and in vivo models after administration of I₂ [1, 2]; 2) expression of PPARG is increased in I₂- or 6IL-supplemented conditions (possibly through an autoregulation mechanism) [2, 10]; 3) the antiproliferative effect of I₂ is only observed in cancer cells, which contain elevated concentrations of AA [2]; and 4) when incubated with total protein, 6IL can activate the PPAR response element (shown by luciferase transactivation assays) and is capable of inducing MCF-7 cells to accumulate lipid droplets in the same manner as the highly specific agonist rosiglitazone [10]. Previously, our group showed that the molecular antiproliferative/apoptotic actions of the 6IL/PPARG complex include the activation of p53 and the consequent increase of p21 expression, thereby inducing cell arrest and Bax-caspase expression, which activates the intrinsic apoptosis pathway [1, 28, 29]. GW9662 irreversibly modifies Cys²⁸⁵ in the PPARG ligand-binding domain with an IC₅₀ in the nanomolar range [40], as compared to the micromolar IC₅₀ of 6IL [1, 10]. This very high affinity can explain the almost complete inhibition by GW9662 observed in control cells. However, proliferation was not totally blocked in cells overexpressing PPARG. By its nature, the adenoviral system forces the cell to maintain unregulated expression; therefore, it is possible that the GW9662 concentration was not sufficient to saturate the PPARGs due either to their overexpression from the vector or to well-established, positive, autoregulatory mechanisms that maintain a high and continuous expression of PPARG [41, 42]. In contrast, the 6IL-induced effect on apoptosis is totally blocked by GW9662 in both control and PPARG-overexpressing cells. Thus, partial PPARG blockage may unmask this dual action of 6IL, in which only a few free PPARG receptors are required for the antiproliferative effect (maybe cell cycle arrest), but additional available receptors are needed to induce apoptosis. Similar dose-dependent responses of PPARG ligands have been described in the literature previously, showing induction of arrest at low concentrations, whereas at high levels they trigger apoptosis [43, 44]. Moreover and although molecular mechanisms for these preferential responses have not been explored, differential recruitment of coactivator cannot be excluded. More than 300 cofactors (coactivators, coregulators, corepressors, etc.) have been identified for the nuclear receptor family. It has been shown that these elements interact with one another and the same ligand modify transcription of many genes [45]. Interestingly, in the PPARG-overexpressing cells, 6IL administration also induces increased expression of FASN, a PPARG-regulated gene that is related to differentiation [46, 47]. This observation is consistent with the differentiation effect of 6IL, observed as lipid accumulation in MCF-7 cells [10].
In relation with silencing the expression of PPARG by molecular tools, our results show that the proliferation rate of RNAi-PPARG MCF-7 cells was two-fold greater than that of MCF-7 control cells, corroborating similar reports in other cancer cells [48]. The findings that MCF-7 cells with PPARG knockdown are insensitive to both the antiproliferative/apoptotic as well as to the anti-migratory effects of 6IL are clear indications that these receptors have an important role in the antineoplastic actions of I2 or 6IL. The next step is to determine if 6IL affects the cell’s invasive characteristics, since the activity of some metalloproteinases and other invasive markers has been blocked by PPARG ligands in several cancers [49, 50].

Finally, it has been described that I2 or 6IL induces apoptosis effects through at least two pathways: AIF/PARP1 and Bax-caspases [1, 9]; Bonofiglio et al. [51] reports that PPARG is able to activate the promoter of the FasL gene, thereby inducing extrinsic apoptosis in MCF-7 cells; this observation was reinforced recently by similar findings in human colorectal cancer cells [52]. In the present work we explored if the extrinsic apoptotic pathway is activated by the 6IL/PPARG complex. Our results show that caspase-8 activity is not increased by I2 or by 6IL treatment; therefore, it seems that the apoptotic effects of I2 and 6IL are mediated exclusively by intrinsic apoptosis pathways.

**Conclusion**

In summary, our data demonstrate that the antitumor effects of 6IL are mediated by PPARG; moreover, the induction of FASN expression strengthens previous observations that 6IL also exerts differentiating effects (adipogenetic induction [10]). 6IL inhibits migration, an effect that may involve PPARG activation. Additionally, 6IL-induced apoptosis does not involve an extrinsic apoptotic pathway. Together, these data reinforce the notion that 6IL is a mediator of I2 effects, and it strengthens the proposal that I2 can be a useful adjuvant in treatment of cancer in tissues that take up iodine.

**Methods**

**Materials and cell culture**

Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), penicillin/streptomycin, puromycin and trypsin solution were supplied by Gibco (Grand Island, NY, USA). Arachidonic acid (AA) (purity >99 %) was used to synthesize 6IL was from Calbiochem (La Jolla, CA, USA). GW9662 (purity >98 %), a specific PPARG antagonist, was obtained from Sigma-Aldrich (St. Louis, MO, USA). All other chemicals were of the highest grade of purity commercially available. The breast cancer cell line MCF-7 was obtained from ATCC®. The cells were maintained in Basal Medium (DMEM supplemented with 10 % FBS, 100 U/mL penicillin, 100 μg/mL streptomycin) at 37 °C and 5 % CO2 prior to experiments.

**Chemical synthesis of 6IL**

6IL was synthesized with a modification of the method of Monteagudo [53]. Briefly, to a solution of AA (65 mg) in acetonitrile (0.8 mL) was added a solution of iodine (156 mg) in acetonitrile (8 mL) at 4 °C. The solution was kept under N2, stirred for 4 h at room temperature and protected from light. The solution containing crude product was concentrated under low nitrogen flow to 0.5 ml and separated on preparative TLC using the solvent system CH2Cl2/MeOH (97:5:2.5). The reaction products, AA (rf: 0.5) and 6IL (rf: 0.88) standards were visualized by iodine vapors, and the 6IL synthesized was eluted with the same solvent and concentrated under low nitrogen flow.

**Adenoviral infection**

Recombinant adenoviruses expressing human PPARG (AdPPARG) were provided by Dr. Steals (Institut Pasteur de Lille, France). Adenovirus expressing GFP (AdGFP), provided by Dr. Hernandez-Gutiérrez (Universidad Panamericana, México), was used to confirm infection and as control. Viruses were multiplied in HEK-293 cells (provided by Dr. Martínez-Torres, Instituto de Neurobiología UNAM, México). Adenoviral titer was determined by the MOI (multiplicity of infection) test (AdEasy™ Vector System, application manual version 1.4). Prior to treatment with GW9662 and/or 6IL, MCF-7 cells were infected at an MOI of 50 for 24 h in basal medium.

**Stable transfection with shRNA against PPARG (RNAi-PPARG)**

Retroviral silencing plasmid (HuSH™) containing a short, specific hairpin with RNA interference for PPARG, a puromycin resistance gene, a tGFP gene and a U6 promoter was obtained from Origen Technologies, Inc. (Rockville, MD, USA) (RNAi-PPARG cells). A similar plasmid but with a scrambled sequence of the short RNAi hairpin against PPARG (Scramble-PPARG cells) was used as internal control. MCF-7 cells were transfected with 5 μg of plasmid and Xfect™ Transfection Reagent (Clontech Laboratories, Mountain View, CA, USA) according to the manufacturer’s instructions, and they were maintained in culture for 48 h; after this time the transfected cells were selected with 1.0 μg/mL puromycin daily over 2 weeks and expanded. Transfection of the cells was confirmed by tGFP expression using an IX50 Olympus microscope with inverted reflected light fluorescence system (Olympus Inc., NY, USA), or by an Agilent 2100 bioanalyzer using an On-Chip flow cytometry
system (Agilent Technologies, USA). Knock-down of PPARG expression was evaluated by quantitative real time PCR (qPCR) with the specific Hydrolysis Probes (Sigma-Aldrich Co., MO) shown in Table 1 and by Western Blot. The selected and stably transfected population was maintained under “light pressure” (0.5 μg/mL puromycin) over the course of the experiments.

**Experimental groups**

The experiments were carried out on AdPPARG-MCF-7-infected cells, on Scrambled- or RNAi-PPARG-MCF-7-transfected cells and on wild-type MCF-7 cells. The cells were cultured at a density of 5 x 10^5 cells in 60-mm culture dishes (Nalge Nunc International, Naperville, IL) for qPCR assays; 4 x 10^4 cells/well in 24-well culture plates for proliferation assays, 2 x 10^5 cells in 60-mm culture dishes for apoptosis experiments, 3 x 10^6 cells in 100-mm culture dishes for Western blot assays, 8 x 10^5 cells in 60-mm culture dishes for wound-healing assays, and 5 x 10^6 cells in 100-mm culture dishes for caspase-8 activity assays. All cells were seeded in complete basal medium and incubated for 24 h before treatment; at the beginning of experiments the medium was changed to low serum (0.5 %)-containing medium. The cells were treated for 24, 48, 72 or 96 h, (depending on the experiment) at 37 °C with 10 μM 6IL, 0.5 μM GW9662 or vehicle (ethanol) diluted before application in low serum-containing medium. In the GW9662/6IL-treated group, GW9662 was administered 2 h prior to 6IL treatment.

**Quantitative PCR**

Total RNA was extracted from cells using TRizol™ reagent (Life Technologies, Thermo Fischer Scientific, MA, USA) according to the manufacturer’s instructions. Two micrograms of total RNA was reversed transcribed using the Superscript II system (Invitrogen, Carlsbad, CA). qPCR was performed on the sequence detector system Roto-Gene 3000 (Corbett Research, Mortlake, Australia) using SYBR green as a marker for DNA amplification. The reaction was performed with 1 μL cDNA template and the Maxima SYBR Green/ROX qPCR Master Mix (Thermo Fischer Scientific, MA), using 40 cycles of three-step amplification (94 °C for 30 s, 55–62 °C for 30 s, 72 °C for 30 s) and the gene-specific primers listed in Table 1. PCR generated only the expected specific amplicon, which was demonstrated in each case by the melting temperature profile (dissociation curve) and by electrophoresis of 5 μL of the PCR product through a 2 % agarose gel in TAE buffer then visualization by ethidium bromide. No PCR products were observed in the absence of template. Gene expression was calculated using the D cycle threshold method and normalized to the content of ACTB, a non-regulated housekeeping gene. All measurements were performed in triplicate.

**Western blot**

Pellets of whole protein were obtained from lysed cells using RIPA buffer with complete Mini, EDTA-free protease inhibitor cocktail tablets (Roche Diagnostics GmbH, Germany). The extracted proteins were quantified by the Bradford method (Bio-Rad protein assay; Hercules, CA) and analyzed by Western blot. SDS polyacrylamide gel electrophoresis was performed as described [10], using stacking and resolving gels (the latter with 15 % acrylamide). Samples containing 50 μg of protein were applied to each lane. After electrophoresis, the proteins were electrotransferred to a nitrocellulose membrane (Bio-Rad, Germany), which was then blocked overnight with TBS containing 5 % non-fat dry milk. The membranes were rinsed and treated with polyclonal anti-PPARG antibody (sc-7196, 57 kDa, 1:1000, Santa Cruz Biotechnology Inc., USA) and anti-ACTB (sc-1616, 43 kDa, 1:10,000, Santa Cruz Biotechnology Inc.) as a protein-loading control. Protein bands were visualized using a chemiluminescent detection system (ECL, Amersham Biosciences, UK). Densitometry was performed with Image Lab™ software (Bio-Rad Laboratories, CA, USA), and chemiluminescence was normalized to the level of ACTB protein.

**Proliferation assays**

The effects on proliferation of 10 μM 6IL, 0.5 μM GW9662 and the GW9662/6IL mixture were analyzed using the Trypan Blue dye-exclusion assay. The cells (4 x 10^4/well) were cultured in DMEM supplemented with 10 % FBS on 24-well culture plates. Control cells were treated with 0.1 % ethanol (solvent for 6IL). After a 72-h treatment, the cells were harvested with trypsin-EDTA 0.05 % (Life Technologies Brand of Thermo Fischer Scientific, MA, USA). Trypan Blue (0.4 %) was added; those cells that excluded the dye were counted with a hemocytometer under the microscope (Leica Inverted Microscope DMIL model, Germany); proliferation is reported as fold change with respect to control.

**Apoptosis assays**

Apoptosis was assessed by detecting phosphatidylserine on the external surface of the cell membrane with annexin V conjugated to the Cy5 fluorophore. To mark cells with intact cell membranes, Calcein-AM was used. Apoptosis was assessed by an Agilent Bioanalyzer 2100 and apoptosis kit following the manufacturer’s instructions (Agilent Technologies, USA). Briefly, after treatment the cell density was adjusted to 1 x 10^6 per mL in 200 μL basal medium, and 200,000 cells were transferred to a 1.5-mL microtube and centrifuged at 2500 rpm for 3 min; the supernatant was discarded. The pellet was re-suspended in 200 μL of 1X Binding Buffer (provided by the manufacturer), and 1 μL of Annexin V (Abcam®, UK) was added and incubated at room temperature for 15 min in the dark at 37 °C; finally, 5 μL of 10 μg/mL propidium iodide solution was added; the samples were then analyzed by flow cytometry.
10 min; after centrifugation at 2500 rpm for 3 min the supernatant was removed, and 1 μL each of Calcein-AM and Fluorolink Cy5 in 200 μL of Binding Buffer were added to the pellet and incubated for 10 min. Finally, the cells were collected by centrifugation and resuspended in Cell Buffer (provided by the manufacturer). A 10-μL aliquot of cells from each treatment was placed on the cell fluorescence LabChip® together the solutions provided in the kit. The apoptotic cells are reported as a percentage of the number of events; this population is delimited in a standardized region by the program CellChip Agilent 2100 Expert software (Agilent Technologies, USA).

Wound-healing assay
RNAi-PPARG MCF-7 cells, Scramble-PPARG MCF-7 cells and wild-type MCF-7 cells, 8 × 10⁵ in each case, were seeded on 60-mm culture plates and incubated at 37 °C and 5 % CO₂. After 24 h, the attached cells were scratched three times in parallel with a 1000-μL pipette tip (~377 μm) and treated with 10 μM 6IL or vehicle (ethanol) for 24 h. After this time, three new parallel wounds were performed as width control; the number of migrating cells was counted by the number of cells inside this width control. The count was measured by Leica Application Suite Version 2.8.1., and the images were captured with a 10× objective lens using a Leica DM 2500 microscope and DFC 420 camera (Leica Microsystems, CMS GmbH, Germany). The results are presented as number of migrating cells of treated (6IL) vs. control (Ctrl) groups (mean ± SD). At least three fields were analyzed for each plate, and each group was analyzed in three independent experiments.

Caspase-8 activity assay
The caspase-8/FLICE activity was measured using a commercial kit (ApoTarget, Invitrogen Co., CA, USA) according to manufacturer’s instructions. Briefly, 5 × 10⁶ MCF-7 cells were collected after a 48-h incubation with I₂ or 6IL. The cell pellet was lysed, and an aliquot containing 200 μg of protein was incubated with DTT (10 mM) and a colorimetric substrate, IETD-p-nitroanilide; (pNA, final concentration 200 μM) at 37 °C for 120 min in the dark. The samples were then read in the spectrophotometer at 405 nm. The absorbance of pNA from a treated sample was compared with an untreated control to determine the fold increase in caspase-8 activity.

Statistical analysis
One- or two-way ANOVA was performed to determine the significance of differences between groups, followed by Tukey’s test for the significance of differences among multiple experimental groups. Data are expressed as mean ± standard deviation (SD), and values with P < 0.05 were considered statistically significant. In the figures, an asterisk indicates significant differences with respect to the control (P < 0.05), and different letters indicate significant differences between groups (P < 0.05).

Competing interests
The authors declare that they have no competing interests.

References
1. Arroyo-Helguera O, Rojas E, Delgado G, Aceves C. Signaling pathways involved in the antiproliferative effect of molecular iodine in normal and tumoral breast cells: evidence that 6-iodolactone mediates apoptotic effects. Endocr Relat Cancer. 2008;15:1003–11.
2. Aceves C, García-Solís P, Arroyo-Helguera O, Vega-Riveroll L, Delgado G, Anguiano B. Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR). Mol Cancer. 2009;83.
3. Nava-Villalba M, Aceves C. 6-Iodolactone, key mediator of antitumoral properties of iodine. Prostaglandins Other Lipid Mediat. 2014;112C:27–33.
4. García-Solís P, Alfaro Y, Anguiano B, Delgado G, Guzman RC, Nandi S, et al. Inhibition of N-methyl-N-nitrosourea-induced mammary carcinogenesis by molecular iodine (I2) but not by iodide (I⁻) treatment evidence that I₂ prevents cancer promotion. Mol Cell Endocrinol. 2005;236:49–57.
5. Arroyo-Helguera O, Anguiano B, Delgado G, Aceves C. Uptake and antiproliferative effect of molecular iodine in the MCF-7 breast cancer cell line. Endocr Relat Cancer. 2006;13:1147–58.
6. Rösner H, Torremante P, Möller W, Gärnér R. Antiproliferative/cytotoxic activity of molecular iodine and iodolactones in various human carcinoma cell lines. No interfering with EGF-signaling, but evidence for apoptosis. Exp Clin Endocrinol Diabetes. 2010;118:410–9.
7. Gärnér R, Rank P, Ander B. The role of iodine and delta-iodolactone in growth and apoptosis of malignant thyroid epithelial cells and breast cancer cells. Horm (Athens). 2010;9:60–6.
8. Aranda N, Sosa S, Delgado G, Aceves C, Anguiano B. Uptake and antitumoral effects of iodine and 6-iodolactone in differentiated and undifferentiated human prostate cancer cell lines. Prostate. 2013;73:31–41.
Nava-Villalba et al. Molecular Cancer (2015) 14:168

9. Shrivastava A, Tixari M, Sinha RA, Kumar A, Balapure AK, Bajpai VK, et al. Molecular iodine induces caspase-independent apoptosis in human breast carcinoma cells involving the mitochondria-mediated pathway. J Biol Chem. 2006;281:19762–71.

10. Nuñez-Anita RE, Arroyo-Helguera O, Cajero-Juárez M, López-Bojorquez L, Aceves C. A complex between 6-iodolactone and the peroxisome proliferator-activated receptor type gamma may mediate the antineoplastic effect of iodine in mammary cancer. Prostaglandins Other Lipid Mediat. 2009;89:34–42.

11. Michilli L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer. 2004;4:61–70.

12. Tachibana K, Yamasaki D, Ishimoto K, Doi T. The role of PPARs in cancer. PPAR Res. 2008;2008:102737.

13. Nunez-Anita RE, Cajero-Juárez M, Aceves C. Peroxisome proliferator-activated receptors: role of isofrom gamma in the antineoplastic effect of iodine in mammary cancer. Curr Cancer Drug Targets. 2011;11:775–86.

14. Roberts-Thomson SJ, Snyedwine EG. Characterization of peroxisome proliferator-activated receptor alpha in normal rat mammary gland and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced mammary gland tumors from rats fed high and low fat diets. Toxicol Lett. 2000;118:79–86.

15. Suchanek KM, May FJ, Robinson JA, Lee WJ, Holman NA, Monteith GR, et al. Peroxisome proliferator-activated receptor alpha in the human breast cancer cell lines MCF-7 and MDA-MB-231. Mol Carcinog. 2002;34:165–71.

16. Germani P, Staels B, Dacquet C, Spéding M, Laudet V. Overview of nomenclature of nuclear receptors. Pharmacol Rev. 2006;58:685–704.

17. Michilli L, Weinberger JP, Chantoni V, Glass CK, Gonzalez-Fanjul E, et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev. 2006;58:726–41.

18. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asoh H, et al. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibitor bind growth and induce apoptosis of human breast cancer cells in vitro and in BNO mice. Proc Natl Acad Sci U S A. 1998;95:8806–11.

19. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KL, Zhang M, et al. Peroxisome proliferator-activated receptor gamma inhibits growth of breast tumour cells and promotes the survival of breast cancer stem cells. Cell Death Differ. 2012;19:1208–14.

20. Yin Y, Russell RG, Dettin LE, Bai R, Wei ZL, Kozikowski AP, et al. Peroxisome proliferator-activated receptor gamma coactivator. Biochem Pharmacol. 2004;67:465–9.

21. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asoh H, et al. Trogilitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem Pharmacol Res Commun. 2001;286:916–22.

22. Lapillonne H, Konopleva M, Tao T, Gold D, McQueen T, Sutherland RL, et al. Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res. 2003;63:926–39.

23. Yin Y, Russell RG, Dettin LE, Bai R, Wei ZL, Kozikowski AP, et al. Perioxidase proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res. 2005;65:3950–7.

24. Papi A, Guarnieri T, Grancini D, Ceccherelli C, Taffurelli M, et al. Nuclear receptors agonists exert opposing effects on the inflammation dependent tumor growth and angiogenesis. Cancer Res. 2005;65:3950–7.

25. Papi A, Storci G, Santini D, Ceccarelli C, Taffurelli M, et al. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor growth and angiogenesis in mice bearing colon tumor xenografts. Neoplasia. 2003;5:532–9.

26. Eskin BA, Grotkowski CE, Connolly CP, Ghent WR. Different tissue responses of PPARgamma activation. Br J Pharmacol. 2002;143:168.

27. Koirala K, Wan Y, Liu Y, Wang X, Cui W, Wang C, et al. Effects of peroxisome proliferator-activated receptor-gamma coactivator. Cancer Res. 2005;65:3950–7.

28. Bogacka I, Xie H, Bray GA, Smith SR. The effect of pioglitazone on prostate cancer cells through inhibition of the CXCR4/CXCL12 axis. Mol Med Rep. 2014;10:695–700.

29. Garcia-Bates TM, Pelsak SL, Baglione CJ, Maggini SB, Bernstein SH, Phipps RP. Peroxisome proliferator-activated receptor-gamma overexpression and knockdown: impact on human B cell lymphoma proliferation and survival. Cancer Immunol Immunother. 2009;58:1071–83.

30. Qin L, Gong C, Chen AM, Guo FJ, Xu F, Ren Y, et al. Peroxisome proliferator activated receptor γ agonist rosiglitazone inhibits migration and invasion of prostate cancer cells through inhibition of the CXCR4/CXCL12 axis. Mol Med Rep. 2014;10:695–700.

31. Reka AK, Narula H, Narala VB, Bommer G, Chen J, Standford TJ, et al. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor antineoplastic adjuvancy, chemoresistance inhibition, and cardioprotection. Mol Cancer. 2013;12:45.

32. Kessler JH. The effect of supraphysiologic levels of iodine on patients with cyclic mastalgia. Breast J 2004;10:328–36.

33. Anguiano S, Ledeza JM, Juarez M, Nuñez F, Aceves C. Therapeutic effect of iodine on benign human prostatic hyperplasia. In: 14th International Thyroid Congress. Paris, France: American Thyroid Association; 2010. p. 0051.

34. Peralta G, Torres J, Delgado G, Dominguez A, De Obladla R, Duarte L, et al. Iodine exhibits dual effects on breast cancer as a co-treatment with anthracyclines: anti-neoplastic synergy and cardioprotector. In: 102nd Annual Meeting, AACR, Orlando, Florida: AACR; 2011. p. 3509/16.

35. Cann SA, van Netten JP, van Netten C. Hypothesis: iodine, selenium and the development of breast cancer. Cancer Causes Control. 2000;11:121–7.

36. Venturi S, Donati FM, Venturi A, Venturi M, Grossi L, Guidi A. Role of iodine in evolution and carcinogenesis of thyroid, breast and stomach. Adv Clin Path. 2000;14:17–25.

37. Venturi S. Is there a role for iodine in breast diseases? Breast. 2001;10:379–82.

38. Ortega-Caltzontzin P, Delgado G, Aceves C, Anguiano B. Iodine uptake and prostate cancer in the TRAMP mouse model. Mol Med. 2013;19:409–16.

39. Dugrillon A, Becknner G, Udelhoven WM, Weber PC, Gartner R. Evidence that an iodolactone mediates the inhibitory effect of iodide on thyroid cell proliferation but not on adenosine 3′5′-monophosphate formation. Endocrinology. 1990;127:337–43.

40. Dugrillon A, Udelhoven WM, Praver MA, Becknner G, Gartner R. Identification of delta-iodolactone in iodized treated human goiter and its inhibitory effect on proliferation of human thyroid follicles. Horm Metab Res. 1994;26:465–9.

41. Leenitsner LM, Parks DJ, Bledose RK, Cobb JE, Collins JL, Consler TG, et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662.

42. Kadegowda AKG, Bionaz M, Piperova LS, Erdman RA, Loor JJ. Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter lipid storage in vivo. Diabetes Care. 2004;27:1660–6.

43. Viswakarma N, Ia Y, Bai L, Vluggen A, Borensztajn J, Xu J, et al. Coactivators in PPAR-Regulated Gene Expression. PPAR Res. 2010; doi:10.1155/2010/250126.

44. Fujii D, Yoshida K, Tanabe K, Hihara J, Toge T. The ligands of peroxisome proliferator-activated receptor-gamma coactivation. Biochemistry. 2002;41:640–50.

45. Kessler JH. The effect of supraphysiologic levels of iodine on patients with cyclic mastalgia. Breast J 2004;10:328–36.
metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition. Mol Cancer Ther. 2010;9:3221–32.

51. Bonofiglio D, Gabriele S, Aquila S, Qi H, Belmonte M, Catalano S, et al. Peroxisome proliferator-activated receptor gamma activates fas ligand gene promoter inducing apoptosis in human breast cancer cells. Breast Cancer Res Treat. 2009;113:423–34.

52. Yao Y, Li L, Huang X, Gu X, Xu Z, Zhang Y, et al. SERPINA3K induces apoptosis in human colorectal cancer cells via activating the Fas/FasL/caspase-8 signaling pathway. FEBS J. 2013;280:3244–55.

53. Monteagudo ES, Caro HN, Veleiro AS, Pisarev MA, Burton G. Synthesis and characterization of iodinated derivatives of arachidonic acid. An Asoc Quim Argent. 1990;78:31–6.